Literature DB >> 22247283

Different patterns of pulmonary vascular disease induced by type 1 diabetes and moderate hypoxia in rats.

Javier Moral-Sanz1, Jose G Lopez-Lopez, Carmen Menendez, Enrique Moreno, Bianca Barreira, Daniel Morales-Cano, Lucia Escolano, Pilar Fernandez-Segoviano, Eduardo Villamor, Angel Cogolludo, Francisco Perez-Vizcaino, Laura Moreno.   

Abstract

Although type 1 and type 2 diabetes are strongly associated with systemic cardiovascular morbidity, the relationship with pulmonary vascular disease had been almost disregarded until recent epidemiological data revealed that diabetes might be a risk factor for pulmonary hypertension. Recent experimental studies suggest that diabetes induces changes in lung function insufficient to elevate pulmonary pressure. The aim of this study was to assess the effects of diabetes on the sensitivity to other risk factors for pulmonary hypertension. We therefore analysed the effects of the combination of diabetes with exposure to moderate hypoxia on classical markers of pulmonary hypertension. Control (saline-treated) and diabetic (70 mg kg(-1) streptozotocin-treated) male Wistar-Kyoto rats were followed for 4 weeks and exposed to normoxia or moderate normobaric hypoxia (14%) for another 2 weeks. Hypoxia, but not diabetes, strongly reduced voltage-gated potassium currents, whereas diabetes, but not hypoxia, induced pulmonary artery endothelial dysfunction. Both factors independently induced pulmonary vascular remodelling and downregulated the lung bone morphogenetic protein receptor type 2. However, diabetes, but not hypoxia, induced pulmonary infiltration of macrophages, which was markedly increased when both factors were combined. Diabetes plus hypoxia induced a modest increase in diastolic and mean pulmonary artery pressure and right ventricular weight, while each of the two factors alone had no significant effect. The pattern of changes in markers of pulmonary hypertension was different for moderate hypoxia and diabetes, with no synergic effect except for macrophage recruitment, and the combination of both factors was required to induce a moderate elevation in pulmonary arterial pressure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22247283     DOI: 10.1113/expphysiol.2011.062257

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  12 in total

Review 1.  Pulmonary vascular dysfunction in metabolic syndrome.

Authors:  Conor Willson; Makiko Watanabe; Atsumi Tsuji-Hosokawa; Ayako Makino
Journal:  J Physiol       Date:  2018-09-12       Impact factor: 5.182

Review 2.  Pulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1.

Authors:  Rajamma Mathew
Journal:  World J Cardiol       Date:  2014-08-26

3.  The flavonoid quercetin reverses pulmonary hypertension in rats.

Authors:  Daniel Morales-Cano; Carmen Menendez; Enrique Moreno; Javier Moral-Sanz; Bianca Barreira; Pilar Galindo; Rachele Pandolfi; Rosario Jimenez; Laura Moreno; Angel Cogolludo; Juan Duarte; Francisco Perez-Vizcaino
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

4.  Hemoptysis during general anesthesia in a diabetic patient with healed tuberculosis: a case report.

Authors:  Mee Young Chung; Hyeon-Do Jeong; Seul-Gi Kim; Chang Jae Kim
Journal:  Korean J Anesthesiol       Date:  2016-11-25

5.  Hypoxia-induced pulmonary hypertension in type 2 diabetic mice.

Authors:  Minglin Pan; Ying Han; Rui Si; Rui Guo; Ankit Desai; Ayako Makino
Journal:  Pulm Circ       Date:  2017-02-01       Impact factor: 3.017

6.  Hepatocyte-secreted extracellular vesicles modify blood metabolome and endothelial function by an arginase-dependent mechanism.

Authors:  Felix Royo; Laura Moreno; Justyna Mleczko; Laura Palomo; Esperanza Gonzalez; Diana Cabrera; Angel Cogolludo; Francisco Perez Vizcaino; Sebastiaan van-Liempd; Juan M Falcon-Perez
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

7.  Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy.

Authors:  Nura A Mohamed; Robert P Davies; Paul D Lickiss; Blerina Ahmetaj-Shala; Daniel M Reed; Hime H Gashaw; Hira Saleem; Gemma R Freeman; Peter M George; Stephen J Wort; Daniel Morales-Cano; Bianca Barreira; Teresa D Tetley; Adrian H Chester; Magdi H Yacoub; Nicholas S Kirkby; Laura Moreno; Jane A Mitchell
Journal:  Pulm Circ       Date:  2017-06-27       Impact factor: 3.017

8.  Obesity and pulmonary hypertension: a review of pathophysiologic mechanisms.

Authors:  Scott E Friedman; Bruce W Andrus
Journal:  J Obes       Date:  2012-09-03

9.  Associations between diabetes mellitus and pulmonary hypertension in chronic respiratory disease patients.

Authors:  Tomoko Takahashi; Akiomi Yoshihisa; Koichi Sugimoto; Tetsuro Yokokawa; Tomofumi Misaka; Takashi Kaneshiro; Masayoshi Oikawa; Atsushi Kobayashi; Kazuhiko Nakazato; Takafumi Ishida; Yasuchika Takeishi
Journal:  PLoS One       Date:  2018-10-09       Impact factor: 3.240

10.  Cell death-inducing DFF45-like effector C gene silencing alleviates pulmonary vascular remodeling in a type 2 diabetic rat model.

Authors:  Dong-Xin Sui; Hui-Min Zhou; Feng Wang; Ming Zhong; Wei Zhang; Yun Ti
Journal:  J Diabetes Investig       Date:  2017-11-28       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.